Patients, doctors hail 'revolutionary' new drug for pancreatic cancer

Megan Chung, a pancreatic cancer patient, joined a clinical trial for daraxonrasib, an experimental drug nearing regulatory approval that has significantly extended survival rates for the disease. The treatment, considered revolutionary, marks a breakthrough in addressing one of the deadliest cancers, with Chung describing its impact as 'miraculous.'